Review
doi: 10.1016/j.rdc.2004.01.009.
Infliximab treatment of rheumatoid arthritis
Affiliations
- PMID: 15172044
- DOI: 10.1016/j.rdc.2004.01.009
Item in Clipboard
Review
Infliximab treatment of rheumatoid arthritis
Rheum Dis Clin North Am.
2004 May.
Abstract
Infliximab was the first anti-TNF agent used to treat rheumatoid arthritis to provide proof of concept of the role of TNF-alpha in this condition. It has become widely used since, principally as an effective treatment in combination with methotrexate, but also as monotherapy for the treatment of Crohn's disease, ankylosing spondylitis,and psoriatic arthritis. The benefits of infliximab in controlling signs and symptoms, improving quality of life, preventing structural joint damage, and possible healing of bone provide an important option for the treatment of rheumatoid arthritis.
Similar articles
-
Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).Int J Clin Pract. 2001 Apr;55(3):211-6. Int J Clin Pract. 2001. PMID: 11351775 Review.
-
Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.Prescrire Int. 2010 Feb;19(105):30-4. Prescrire Int. 2010. PMID: 20455343 Review.
-
[Infliximab in the treatment of rheumatoid arthritis].Nihon Rinsho. 2002 Dec;60(12):2378-83. Nihon Rinsho. 2002. PMID: 12510365 Review. Japanese.
-
Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.J Rheumatol. 2007 Dec;34(12):2326-33. Epub 2007 Nov 15. J Rheumatol. 2007. PMID: 18050387 Clinical Trial.
-
Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?J Rheumatol. 2006 Feb;33(2):433; author reply 433-4. J Rheumatol. 2006. PMID: 16465676 No abstract available.
Cited by
-
Synthetic and semi-synthetic antioxidants in medicine and food industry: a review.Front Pharmacol. 2025 Jul 22;16:1599816. doi: 10.3389/fphar.2025.1599816. eCollection 2025. Front Pharmacol. 2025. PMID: 40766767 Free PMC article. Review.
-
Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial.Rheumatol Int. 2008 Nov;29(1):53-7. doi: 10.1007/s00296-008-0606-8. Epub 2008 May 22. Rheumatol Int. 2008. PMID: 18496694 Clinical Trial.
-
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.Arthritis Res Ther. 2006;8(4):R112. doi: 10.1186/ar2001. Arthritis Res Ther. 2006. PMID: 16978395 Free PMC article.
-
The role of inflammation in autoimmune disease: a therapeutic target.Front Immunol. 2023 Oct 4;14:1267091. doi: 10.3389/fimmu.2023.1267091. eCollection 2023. Front Immunol. 2023. PMID: 37859999 Free PMC article. Review.
-
Biologics in juvenile idiopathic arthritis: a narrative review.Eur J Pediatr. 2017 Sep;176(9):1147-1153. doi: 10.1007/s00431-017-2960-6. Epub 2017 Jul 20. Eur J Pediatr. 2017. PMID: 28725955 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
